Clinical and molecular genetics of the phosphodiesterases (PDEs)
Cyclic nucleotide phosphodiesterases (PDEs) are enzymes that have the unique function of
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
terminating cyclic nucleotide signaling by catalyzing the hydrolysis of cAMP and GMP. They …
PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer
Abstract The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™),
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …
[HTML][HTML] Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signaling
We investigated the effect of sildenafil in protection against necrosis or apoptosis in
cardiomyocytes. Adult mouse ventricular myocytes were treated with sildenafil (1 or 10 μm) …
cardiomyocytes. Adult mouse ventricular myocytes were treated with sildenafil (1 or 10 μm) …
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity
Background—Sildenafil, a phosphodiesterase-5 inhibitor, induces cardioprotection against
ischemia/reperfusion injury via opening of mitochondrial KATP channels. It is unclear …
ischemia/reperfusion injury via opening of mitochondrial KATP channels. It is unclear …
Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk
OBJECTIVE:: Erectile dysfunction (ED) is often associated with a cluster of risk factors for
coronary artery disease and reduced endothelial function. Acute and chronic administration …
coronary artery disease and reduced endothelial function. Acute and chronic administration …
Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized …
H Porst, F Giuliano, S Glina, D Ralph, AR Casabé… - European urology, 2006 - Elsevier
BACKGROUND: Erectile dysfunction (ED) is a chronic disease; however, therapy is currently
administered as needed with oral phosphodiesterase 5 (PDE5) inhibitors like tadalafil …
administered as needed with oral phosphodiesterase 5 (PDE5) inhibitors like tadalafil …
Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications
The phosphodiesterase type-5 (PDE5) inhibitor, sildenafil, is the first drug developed for
treatment of erectile dysfunction in patients. Experimental data in animals show that …
treatment of erectile dysfunction in patients. Experimental data in animals show that …
Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice
We tested the hypothesis that chronic treatment with sildenafil attenuates myocardial
infarction (MI)-induced heart failure. Sildenafil has potent protective effects against necrosis …
infarction (MI)-induced heart failure. Sildenafil has potent protective effects against necrosis …
A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
K Hatzimouratidis, DG Hatzichristou - Drugs, 2005 - Springer
The field of erectile dysfunction (ED) has been revolutionised over the last two decades.
Several treatment options are available today, most of which are associated with high …
Several treatment options are available today, most of which are associated with high …
Neurorestorative treatment of stroke: cell and pharmacological approaches
J Chen, M Chopp - NeuroRx, 2006 - Elsevier
There is a compelling need to develop cell and pharmacological therapeutic approaches to
be administered beyond the hyperacute phase of stroke. These therapies capitalize on the …
be administered beyond the hyperacute phase of stroke. These therapies capitalize on the …